Harvard Bioscience, Inc provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.
Read More…
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
Phone508-893-8999
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$120.77 million
Profitability
Miscellaneous
Employees519
Next Earnings Date10/24/2019 (Estimated)
OptionableOptionable
Harvard Bioscience (NASDAQ:HBIO) Frequently Asked Questions
What is Harvard Bioscience's stock symbol?
Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."
How were Harvard Bioscience's earnings last quarter?
Harvard Bioscience, Inc. (NASDAQ:HBIO) released its quarterly earnings results on Thursday, July, 25th. The medical instruments supplier reported $0.03 EPS for the quarter, beating the Zacks' consensus estimate of $0.02 by $0.01. The medical instruments supplier had revenue of $29.58 million for the quarter, compared to analyst estimates of $29.30 million. Harvard Bioscience had a negative net margin of 0.46% and a positive return on equity of 5.24%. View Harvard Bioscience's Earnings History.
When is Harvard Bioscience's next earnings date?
What guidance has Harvard Bioscience issued on next quarter's earnings?
Harvard Bioscience issued an update on its FY 2019 earnings guidance on Thursday, July, 25th. The company provided EPS guidance of $0.19-0.21 for the period, compared to the Thomson Reuters consensus estimate of $0.19.
What price target have analysts set for HBIO?
2 Wall Street analysts have issued 12-month price objectives for Harvard Bioscience's shares. Their forecasts range from $2.00 to $2.00. On average, they expect Harvard Bioscience's stock price to reach $2.00 in the next twelve months. This suggests that the stock has a possible downside of 30.1%. View Analyst Price Targets for Harvard Bioscience.
What is the consensus analysts' recommendation for Harvard Bioscience?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Harvard Bioscience.
Has Harvard Bioscience been receiving favorable news coverage?
Media coverage about HBIO stock has trended negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Harvard Bioscience earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave media headlines about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Harvard Bioscience.
Are investors shorting Harvard Bioscience?
Harvard Bioscience saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 1,290,000 shares, an increase of 38.3% from the August 30th total of 933,000 shares. Based on an average daily volume of 326,600 shares, the days-to-cover ratio is currently 3.9 days. Currently, 3.8% of the shares of the stock are short sold. View Harvard Bioscience's Current Options Chain.
Who are some of Harvard Bioscience's key competitors?
Some companies that are related to Harvard Bioscience include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM) and aTyr Pharma (LIFE).
What other stocks do shareholders of Harvard Bioscience own?
Who are Harvard Bioscience's key executives?
Harvard Bioscience's management team includes the folowing people:
- Mr. Jeffrey A. Duchemin, CEO, Pres & Director (Age 53)
- Ms. Kamalam Unninayar, Chief Financial Officer (Age 51)
- Mr. Russell J. Sylvia, VP of Global HR
- Mr. Corey Manchester, VP & Corp. Controller
Who are Harvard Bioscience's major shareholders?
Harvard Bioscience's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Dalton Greiner Hartman Maher & Co. (3.61%), Assenagon Asset Management S.A. (1.16%) and Pasadena Private Wealth LLC (0.07%). Company insiders that own Harvard Bioscience stock include Bertrand Loy, George Uveges, James W Green, Jeffrey Duchemin, Katherine A Eade, Robert E Gagnon and Thomas W Loewald. View Institutional Ownership Trends for Harvard Bioscience.
Which institutional investors are buying Harvard Bioscience stock?
HBIO stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Dalton Greiner Hartman Maher & Co. and Pasadena Private Wealth LLC. Company insiders that have bought Harvard Bioscience stock in the last two years include Bertrand Loy, James W Green, Katherine A Eade and Thomas W Loewald. View Insider Buying and Selling for Harvard Bioscience.
How do I buy shares of Harvard Bioscience?
Shares of HBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Harvard Bioscience's stock price today?
One share of HBIO stock can currently be purchased for approximately $2.86.
How big of a company is Harvard Bioscience?
Harvard Bioscience has a market capitalization of $108.82 million and generates $120.77 million in revenue each year. The medical instruments supplier earns $-2,920,000.00 in net income (profit) each year or $0.15 on an earnings per share basis. Harvard Bioscience employs 519 workers across the globe.View Additional Information About Harvard Bioscience.
What is Harvard Bioscience's official website?
How can I contact Harvard Bioscience?
Harvard Bioscience's mailing address is 84 OCTOBER HILL ROAD, HOLLISTON MA, 01746. The medical instruments supplier can be reached via phone at 508-893-8999 or via email at [email protected]
MarketBeat Community Rating for Harvard Bioscience (NASDAQ HBIO)
MarketBeat's community ratings are surveys of what our community members think about Harvard Bioscience and other stocks. Vote "Outperform" if you believe HBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
